Swetlik, C., Cohen, L. S., Kobylski, L. A., Sojka, E. T., Killenberg, P. C., Freeman, M. P., & Viguera, A. C. (2024). Effects of Prenatal Exposure to Second-Generation Antipsychotics on Development and Behavior Among Preschool-Aged Children: Preliminary Results From the National Pregnancy Registry for Psychiatric Medications. The Journal of Clinical Psychiatry, 85(1).
Cohen, L. S., Church, T. R., Freeman, M. P., Gaccione, P., Caplin, P. S., Kobylski, L. A., Arakelian, M., Rossa, E. T., Chitayat, D., Hernández-Díaz, S., & Viguera, A. C. (2023). Reproductive Safety of Lurasidone and Quetiapine: Update from the National Pregnancy Registry for Psychiatric Medications. Journal of women’s health (2002), 32(4), 452–462.
Viguera, A. C., McElheny, S. A., Caplin, P. S., Kobylski, L. A., Rossa, E. T., Young, A. V., Gaccione, P., Góez-Mogollón, L., Freeman, M. P., & Cohen, L. S. (2023). Risk of Poor Neonatal Adaptation Syndrome Among Infants Exposed to Second-Generation Atypical Antipsychotics Compared to Antidepressants: Results From the National Pregnancy Registry for Psychiatric Medications. The Journal of clinical psychiatry, 84(1), 22m14492.
Freeman, M. P., Szpunar, M. J., Kobylski, L. A., Harmon, H., Viguera, A. C., & Cohen, L. S. (2022). Pregnancy outcomes after first-trimester exposure to buspirone: prospective longitudinal outcomes from the MGH National Pregnancy Registry for Psychiatric Medications. Archives of women’s mental health, 25(5), 923–928.
Szpunar, M. J., Freeman, M. P., Kobylski, L. A., Caplin, P. S., Gaccione, P., Viguera, A. C., Chitayat, D., Hernández-Díaz, S., & Cohen, L. S. (2022). Risk of major malformations in infants after first-trimester exposure to benzodiazepines: Results from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications. Depression and anxiety, 39(12), 751–759.
Viguera, A. C., Vanderkruik, R., Gaccione, P., Caplin, P. S., Kobylski, L. A., Freeman, M. P., & Cohen, L. S. (2022). Breastfeeding practices among women taking second-generation antipsychotics: findings from the National Pregnancy Registry for Atypical Antipsychotics. Archives of women’s mental health, 25(2), 511–516.
Viguera, A. C., Freeman, M. P., Góez-Mogollón, L., Sosinsky, A. Z., McElheny, S. A., Church, T. R., Young, A. V., Caplin, P. S., Chitayat, D., Hernández-Díaz, S., & Cohen, L. S. (2021). Reproductive Safety of Second-Generation Antipsychotics: Updated Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. The Journal of clinical psychiatry, 82(4), 20m13745.
Freeman, M. P., Viguera, A. C., Góez-Mogollón, L., Young, A. V., Caplin, P. S., McElheny, S. A., Church, T. R., Chitayat, D., Hernández-Díaz, S., & Cohen, L. S. (2021). Reproductive safety of aripiprazole: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Archives of women’s mental health, 24(4), 659–667.
Freeman, M. P., Goez-Mogollon, L., Sosinsky, A. Z., Church, T. R., McElheny, S. A., Viguera, A. C., & Cohen, L. S. (2019). The impact of obesity on pregnancy outcomes among women with psychiatric disorders: Results from a prospective pregnancy registry. Journal of psychosomatic research, 123, 109735.
Freeman, M. P., Sosinsky, A. Z., Goez-Mogollon, L., Savella, G. M., Moustafa, D., Viguera, A. C., & Cohen, L. S. (2018). Gestational Weight Gain and Pre-pregnancy Body Mass Index Associated With Second-Generation Antipsychotic Drug Use During Pregnancy. Psychosomatics, 59(2), 125–134.
Cohen, L. S., Góez-Mogollón, L., Sosinsky, A. Z., Savella, G. M., Viguera, A. C., Chitayat, D., Hernández-Díaz, S., & Freeman, M. P. (2018). Risk of Major Malformations in Infants Following First-Trimester Exposure to Quetiapine. The American journal of psychiatry, 175(12), 1225–1231.
Freeman, M. P., Farchione, T., Yao, L., Sahin, L., Taylor, L., Huybrechts, K. F., Nonacs, R., Sosinsky, A. Z., Viguera, A. C., & Cohen, L. S. (2018). Psychiatric Medications and Reproductive Safety: Scientific and Clinical Perspectives Pertaining to the US FDA Pregnancy and Lactation Labeling Rule. The Journal of clinical psychiatry, 79(4), 18ah38120.
Freeman, M. P., Góez-Mogollón, L., McInerney, K. A., Davies, A. C., Church, T. R., Sosinsky, A. Z., Noe, O. B., Viguera, A. C., & Cohen, L. S. (2018). Obstetrical and neonatal outcomes after benzodiazepine exposure during pregnancy: Results from a prospective registry of women with psychiatric disorders. General hospital psychiatry, 53, 73–79.
Park, Y., Hernandez-Diaz, S., Bateman, B. T., Cohen, J. M., Desai, R. J., Patorno, E., Glynn, R. J., Cohen, L. S., Mogun, H., & Huybrechts, K. F. (2018). Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes. The American journal of psychiatry, 175(6), 564–574.
Freeman, M. P., Sosinsky, A. Z., Goez-Mogollon, L., Savella, G. M., Moustafa, D., Viguera, A. C., & Cohen, L. S. (2018). Gestational Weight Gain and Pre-pregnancy Body Mass Index Associated With Second-Generation Antipsychotic Drug Use During Pregnancy. Psychosomatics, 59(2), 125–134.
Panchaud, A., Hernandez-Diaz, S., Freeman, M. P., Viguera, A. C., MacDonald, S. C., Sosinsky, A. Z., & Cohen, L. S. (2017). Use of atypical antipsychotics in pregnancy and maternal gestational diabetes. Journal of psychiatric research, 95, 84–90.
Sosinsky, A. Z., Freeman, M. P., Savella, G. M., Cheng, L. J., Viguera, A. C., & Cohen, L. S. (2017). Delusional Pregnancy Presenting to the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Journal of clinical psychopharmacology, 37(4), 472–474.
Patorno, E., Huybrechts, K. F., Bateman, B. T., Cohen, J. M., Desai, R. J., Mogun, H., Cohen, L. S., & Hernandez-Diaz, S. (2017). Lithium Use in Pregnancy and the Risk of Cardiac Malformations. The New England journal of medicine, 376(23), 2245–2254.
Huybrechts, K. F., Hernández-Díaz, S., Patorno, E., Desai, R. J., Mogun, H., Dejene, S. Z., Cohen, J. M., Panchaud, A., Cohen, L., & Bateman, B. T. (2016). Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA psychiatry, 73(9), 938–946.
Freeman, M. P., Sosinsky, A. Z., Moustafa, D., Viguera, A. C., & Cohen, L. S. (2016). Supplement use by women during pregnancy: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Archives of women’s mental health, 19(3), 437–441.
Cohen, L. S., Viguera, A. C., McInerney, K. A., Freeman, M. P., Sosinsky, A. Z., Moustafa, D., Marfurt, S. P., Kwiatkowski, M. A., Murphy, S. K., Farrell, A. M., Chitayat, D., & Hernández-Díaz, S. (2016). Reproductive Safety of Second-Generation Antipsychotics: Current Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. The American journal of psychiatry, 173(3), 263–270.
Cohen, L. S., Viguera, A. C., McInerney, K. A., Freeman, M. P., Sosinsky, A. Z., Moustafa, D., Marfurt, S. P., Kwiatkowski, M. A., Murphy, S. K., Farrell, A. M., Chitayat, D., & Hernández-Díaz, S. (2016). Reproductive Safety of Second-Generation Antipsychotics: Current Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. The American journal of psychiatry, 173(3), 263–270.
Cohen, L. S., Viguera, A. C., McInerney, K. A., Kwiatkowski, M. A., Murphy, S. K., Lemon, E. L., & Hernández-Díaz, S. (2015). Establishment of the National Pregnancy Registry for Atypical Antipsychotics. The Journal of clinical psychiatry, 76(7), 986–989.
Freeman, M. P. (2015). Psychotropic medication use during pregnancy: changes to the labeling system and the importance of exposure registries. The Journal of clinical psychiatry, 76(7), 990–991.
Huybrechts, K. F., Palmsten, K., Avorn, J., Cohen, L. S., Holmes, L. B., Franklin, J. M., Mogun, H., Levin, R., Kowal, M., Setoguchi, S., & Hernández-Díaz, S. (2014). Antidepressant use in pregnancy and the risk of cardiac defects. The New England journal of medicine, 370(25), 2397–2407.